Bangladeshi Firms Roll Out $12-13 Harvoni Generic
This article was originally published in Scrip
Executive Summary
Bangladeshi firms Incepta Pharmaceuticals and Beximco Pharmaceuticals have now introduced what are probably the first cut-price generic versions of Gilead's money-spinner hepatitis C treatment, Harvoni (the fixed-dose combination of ledipasvir and sofosbuvir), on the domestic market.